U.K. doctors seek review of 12-week gap between doses
LONDON — A major British doctors’ group says the U.K. government should “urgently review” its decision to give people a second dose of the Pfizer-BioNTech coronavirus vaccine up to 12 weeks after the first, rather than the shorter gap recommended by the manufacturer and the World Health Organization.
The U.K., which has Europe’s deadliest coro- navirus outbreak, adopted the policy in order to give as many people as possible a first dose of vaccine quickly. So far almost 5.9 million peo- ple in Britain have received a shot of either a vaccine made by U.S. drugmaker Pfizer and Germany’s BioNTech or one developed by U.K.-Swedish pharmaceutical giant AstraZeneca and Oxford University.
AstraZeneca has said it believes a first dose of its vaccine offers protection after 12 weeks, but Pfizer says it has not tested the efficacy of its jab after such a long gap.
The British Medical Asso- ciation on Saturday urged England’s chief medical officer to “urgently review the U.K.’s current position of sec- ond doses after 12 weeks.”
In a statement, the association said there was “grow- ing concern from the medical profession regarding the delay of the second dose of the Pfizer-BioNTech vaccine as Britain’s strategy has become increasingly isolated from many other countries.”
“No other na t ion has adopted the U.K.’s approach,” said Dr. Chaand Nagpaul, chairman of the BMA council.
He said the WHO had recommended that the second Pfizer vaccine shot could be given up to six weeks after the first but only “in excep- tional circumstances.”
“I do understand the tradeoff and the rationale, but if that was the right thing to do then we would see other nations following suit,” Nagpaul said.
Yvonne Doyle, medical director of Public Health England, defended the decision as “a reasonable scien- tific balance on the basis of both supply and also protecting the most people.”
Researchers in Britain have begun collecting blood samples from newly vaccinated people in order to study how many antibodies they are producing at different intervals, from 3 weeks to 24 months, to get an answer to the ques- tion of what timing is best for the shots.
The doctors’ concerns came a day after government medical advisers said there was evidence that a new variant of the virus first identified in southeast England carries a greater risk of death than the original strain.
Chief Scientific Adviser Patrick Vallance said Friday “that there is evidence that there is an increased risk for those who have the new variant,” which is also more transmissible than the original virus. He said the new strain might be about 30% more deadly, but stressed that “the evidence is not yet strong” and more research is needed.